Apellis EMPAVELI® Injector, a Device to Streamline Self-Administration, OKd by FDA

 

 Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI® Injector. The EMPAVELI Injector is a compact, single-use, on-body device designed to enhance self-administration of EMPAVELI (pegcetacoplan), which is approved for adults with paroxysmal nocturnal hemoglobinuria (PNH).

https://www.globenewswire.com/news-release/2023/10/02/2752610/0/en/Apellis-Announces-U-S-FDA-Approval-of-the-EMPAVELI-Injector-a-Device-to-Streamline-Self-Administration.html